[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341900-105":59,"doc-detail-341900-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-effect-of-tumor-composition-on-the-success-of-adaptive-therapy-the-case-of-metastatic-castrate-resistant-prostate-cancer","The effect of tumor composition on the success of adaptive therapy - The case of metastatic Castrate-Resistant Prostate Cancer","","Prostate-specific antigen (PSA) is widely used for detecting, staging, and monitoring prostate cancer, and it also guides adaptive therapy by alternating treatment according to PSA levels. However, how PSA levels relate to tumor volume is not well understood, partly because different cancer cell types may produce different amounts of PSA. This study compares Zhang et al.’s adaptive therapy protocol with standard care using continuous maximum tolerable dose under different PSA production assumptions. It analyzes time to competitive release as a proxy for disease progression. Adaptive therapy yields a longer time to competitive release than standard care across assumptions, while treatment cycles and applicability depend strongly on which cell types produce PSA. Results highlight the need for deeper understanding of patient-specific PSA dynamics to improve adaptive therapy effectiveness.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-effect-of-tumor-composition-on-the-success-of-adaptive-therapy-the-case-of-metastatic-castrate-resistant-prostate-cancer/341900/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-effect-of-tumor-composition-on-the-success-of-adaptive-therapy-the-case-of-metastatic-castrate-resistant-prostate-cancer/341900.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does PSA play in prostate cancer care and adaptive therapy?","Question",{"text":112,"@type":113},"PSA is used for detection, staging, and treatment monitoring. In adaptive therapy, treatment is alternated based on PSA levels to reflect patient-specific response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does this study compare adaptive therapy with standard care?",{"text":117,"@type":113},"It compares Zhang et al.’s adaptive therapy protocol with standard care that applies continuous maximum tolerable dose. The comparison is performed under different assumptions about how cell types contribute to PSA production.",{"name":119,"@type":110,"acceptedAnswer":120},"Why can Zhang et al.’s adaptive therapy protocol become inapplicable under some PSA production assumptions?",{"text":121,"@type":113},"If testosterone-independent cells are the sole PSA producers, PSA levels may never drop to half of the initial value, preventing therapy discontinuation according to the adaptive protocol.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341900,1790390987,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","PLOS ONE  \nOPEN ACCESS  \nCitation: Salvioli M, Vandelaer L, Baena E, Schneider K, Cavill R, Staňkov´a K (2024) The effect of tumor composition on the success of adaptive therapy: The case of metastatic Castrate-Resistant Prostate Cancer. PLoS ONE 19(9): e0308173 .  \n[https://doi.org/10.1371/journal.pone.0308173](https://doi.org/10.1371/journal.pone.0308173)  \n[Editor:](Editor: Ebenezer Wiafe)[ Ebenezer Wiafe](Editor: Ebenezer Wiafe), [University of](University of) Health and Allied Sciences, GHANA  \nReceived: March 22, 2023  \nAccepted: July 18, 2024  \nPublished: September 26, 2024  \nCopyright: © 2024 Salvioli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the manuscript and its Supporting information files.  \nFunding: This study was supported by the Cancer Research UK Manchester Institute in the form of a grant [C5759/A20971] to EB, the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant [955708] to KS, and the Dutch Research Council in the form of projects [ENWPR.020.006;  \nRESEARCH ARTICLE  \nThe effect of tumor composition on the success of adaptive therapy: The case of metastatic Castrate-Resistant Prostate Cancer  \nMonica Salvioli1,2 *, Len Vandelaer2, Esther Baena3, Katharina Schneider2, Rachel Cavill2, Kateřina Staňkov´a1  \n1 Evolutionary Game Theory Lab, Faculty of Technology, Policy and Management, Delft University of Technology, Delft, The Netherlands, 2 Department of Advanced Computing Sciences, Maastricht University, Maastricht, The Netherlands, 3 Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom  \n* [m.salvioli@maastrichtuniversity.nl](m.salvioli@maastrichtuniversity.nl)  \nAbstract  \nProstate-specific antigen (PSA) is the most commonly used serum marker for prostate cancer. It plays a role in cancer detection, treatment monitoring, and more recently, in guiding adaptive therapy protocols, where treatment is alternated based on PSA levels. However, the relationship between PSA levels and tumor volume remains poorly understood. Empirical evidence suggests that different cancer cell types produce varying amounts of PSA. Despite this, current mathematical cancer models often assume either that all cell types contribute equally to PSA levels or that only certain subpopulations produce PSA at fixed rates. In this study, we compare Zhang et al.’s classical adaptive therapy protocol with the standard of care, which involves continuous maximum tolerable dose treatment, under different assumptions regarding PSA production. Specifically, we explore the possibility that testosterone-dependent , testosterone-producing, and testosterone-independent cells contribute to PSA production to varying degrees. We use the time to competitive release as a proxy for the time to disease progression. Our findings indicate that adaptive therapy consistently results in a longer time to competitive release compared to the standard of care, regardless of the assumptions about PSA production. However, when testosterone-independent cells are the sole PSA producers, Zhang et al.’s adaptive therapy protocol becomes inapplicable, as PSA levels never fall to half of their initial value, preventing therapy discontinuation. Additionally, we observe that the number and duration of treatment cycles in adaptive therapy are highly sensitive to assumptions about how much each cell type contributes to PSA production. Overall, our results emphasize the need for a deeper understanding of patientspecific PSA dynamics, which could enhance the effectiveness of adaptive therapy in prostate cancer treatment.  \nIntroduction  \nProstate-specific antigen (PSA) is an enzyme produced by both normal and cancerous prostate ep","cbCaigqpsczcKyUd","https://ap.wps.com/l/cbCaigqpsczcKyUd","pdf",1594196,15,"English","# Abstract\n# Introduction\n## PSA as a clinical marker\n## Adaptive therapy and PSA-guided treatment decisions","[{\"question\":\"What role does PSA play in prostate cancer care and adaptive therapy?\",\"answer\":\"PSA is used for detection, staging, and treatment monitoring. In adaptive therapy, treatment is alternated based on PSA levels to reflect patient-specific response.\"},{\"question\":\"How does this study compare adaptive therapy with standard care?\",\"answer\":\"It compares Zhang et al.’s adaptive therapy protocol with standard care that applies continuous maximum tolerable dose. The comparison is performed under different assumptions about how cell types contribute to PSA production.\"},{\"question\":\"Why can Zhang et al.’s adaptive therapy protocol become inapplicable under some PSA production assumptions?\",\"answer\":\"If testosterone-independent cells are the sole PSA producers, PSA levels may never drop to half of the initial value, preventing therapy discontinuation according to the adaptive protocol.\"}]","The effect of tumor composition on the success of adaptive therapy - The case of metastatic Castrate-Resistant Prostate Cancer | PDF",1790044294,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aec52db1fe02488b19327949add7707c.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efa4dcee62ea6457353f4f679953884e.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9e80cdb8f17cb29c5b5ae5233b08a13.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b0d8f689b035a0bcb28d343258671c5.webp",980,1268]